China Approves World’s First CAR-T Therapy for Solid Tumors
A landmark regulatory approval in China has cleared the way for Satri-cel, the first CAR-T cell therapy designed to combat solid tumors. The treatment targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma, providing a vital option for patients who have exhausted at least two previous lines of standard therapy.
The National Medical Products Administration’s green light for Satri-cel, also known as CT041 or Kaileimei, signals a shift in oncology. For years, the scientific community has struggled to translate the success of CAR-T treatments from blood cancers to solid tumors. This breakthrough marks a transition point in medical research, with Jiahui International Cancer Center in Shanghai now preparing to integrate the therapy into its existing multidisciplinary oncology program.
Dr. Linli Xuan, Chief of Medical Oncology at the center, described the approval as a milestone that solidifies China’s role in developing transformative cancer treatments. As international interest in these innovations grows, the facility is positioning itself as a primary access point for both domestic and global patients. The center utilizes a streamlined pathway involving precision medicine, surgical oncology, and specialized cellular therapy support to manage patients who travel from abroad for advanced care.
Comments (0)
No comments yet. Be the first!